# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
BrainStorm Cell Therapeutics Inc. (NASDAQ:BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative dise...
Brainstorm Cell (NASDAQ:BCLI) reported quarterly losses of $(0.05) per share which beat the analyst consensus estimate of $(0.0...
- SEC Filing
Bob Dagher, MD, Promoted to Chief Medical Officer Dr. Stacy Lindborg Stepping Down as Co-CEO and Transitioning to Board of D...
BrainStorm Cell Therapeutics Inc. (NASDAQ:BCLI, ", , the Company", , )))), a leading developer of cellular therapies fo...